Other new targets involve the fibroblast activation protein and the cholecystokinin-2 receptors, where the ligand minigastrin opens new possibilities for the management of medullary thyroid carcinoma. The gene discussed is CCKBR; the disease is medullary thyroid gland carcinoma.